Crowe Suzanne 4

What Happened

• Suzanne Crowe, a director of AVITA Medical, received awards reported on June 3, 2026 that consist of 22,214 restricted stock units (RSUs) and a grant of 16,133 stock options. The options have an exercise price of $3.77 (the Nasdaq closing price on the grant date). These are awards/grants (not open‑market purchases or sales).

Key Details

• Transaction/grant date: January 20, 2026 (grant date); ownership change/effectiveness and report period: June 3, 2026; Form 4 filed June 4, 2026.
• RSUs: 22,214 RSUs granted; each RSU represents a contingent right to one share and are subject to time-based vesting — they vest 12 months after the January 20, 2026 grant date (i.e., around Jan 20, 2027). Grant required and received stockholder approval on June 3, 2026.
• Options: 16,133 options granted to non-executive directors, exercise price $3.77 per share (grant approved by stockholders on June 3, 2026). The Form 4 reports these as a derivative award (acquisition amount shown as $0.00 on the filing).
• Holdings note: Footnote indicates inclusion of 22,990 CDIs that translate into 4,598 common shares in the reported holdings and that the RSUs include unvested awards.
• Timeliness: The Form 4 was filed the day after the reported ownership change (June 3 → filed June 4), so the filing appears timely.

Context

• These were grants/awards, not exercises or open‑market trades. RSUs are time‑vested compensation and will convert to shares only if vesting conditions are met; options are not exercised here. Such awards are common for board compensation and are not, by themselves, a direct buy/sell signal about the insider’s view of the stock.